Citadel Advisors
EIGR

Citadel Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Citadel Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7
Closed -$45 – 15714
2023
Q4 		$45 Buy
+7
New +$62 ﹤0.01% 14151
2023
Q2 		– Sell
-447
Closed -$12K – 15500
2023
Q1 		$12K Sell
447
-856
-66% -$39.8K ﹤0.01% 13442
2022
Q4 		$46.1K Buy
1,303
+943
+262% +$113K ﹤0.01% 12235
2022
Q3 		$81K Buy
+360
New +$88.5K ﹤0.01% 11278
2021
Q4 		– Sell
-557
Closed -$112K – 15039
2021
Q3 		$112K Buy
557
+10
+2% +$2.38K ﹤0.01% 12738
2021
Q2 		$140K Sell
547
-426
-44% -$106K ﹤0.01% 12572
2021
Q1 		$258K Sell
973
-160
-14% -$50.4K ﹤0.01% 11175
2020
Q4 		$418K Buy
1,133
+110
+11% +$31.6K ﹤0.01% 8470
2020
Q3 		$250K Buy
+1,023
New +$318K ﹤0.01% 8439
2015
Q4 		– Sell
-15
Closed -$7K – 9320
2015
Q3 		$7K Sell
15
-15
-50% -$7.96K ﹤0.01% 8577
2015
Q2 		$17K Sell
30
-3
-9% -$8.3K ﹤0.01% 8242
2015
Q1 		$280K Buy
+33
New +$288K ﹤0.01% 5748

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Citadel Advisors's EIGR Position: Q1 2024 in Review

Citadel Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 334 shares — an estimated $2.25K sold.

Citadel Advisors first reported a position in EIGR in Q1 2015 and held it in 17 quarters. The position peaked at $11.7M in Q4 2020. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Citadel Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 334 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $2.25K.
  • Citadel Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 17 quarters.
  • Citadel Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $11.7M in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.